Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$37.59M+123.03%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carrie A. Lachance
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 467
- Beta
- 1.38
- Country
- US
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 5.66
Financials
Revenue
$37.59M+123.0%Net Income
$3.16MEBITDA
$7.37M+209.4%Free Cash Flow
$8.10M+241.0%EPS (diluted)
$0.15Shares Outstanding (diluted)
21.07M-7.0%Operating Expenses
$16.52MCash & Debt
$9.11MReturn of Capital
$605.0KRevenue by Segment (annual)
$150.63MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $143.44M | $6.63M | $0.32 |
| 2024 | $134.86M | $2.35M | $0.11 |
| 2023 | $125.78M | $872.0K | $0.04 |
| 2022 | $109.91M | $18.0K | $0.00 |
| 2021 | $102.38M | $1.42M | $0.07 |
| 2020 | $97.39M | $17.33M | $0.86 |
| 2019 | $81.11M | $1.36M | $0.07 |
| 2018 | $67.14M | $-1.09M | $-0.05 |
| 2017 | $71.08M | $-20.71M | $-0.91 |
| 2016 | $70.50M | $-222.0K | $-0.01 |
| 2015 | $72.13M | $3.74M | $0.17 |
| 2014 | $66.49M | $3.36M | $0.15 |
| 2013 | $62.28M | $1.67M | $0.08 |
| 2012 | $58.83M | $-1.49M | $-0.07 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.47
- Implied price
- $13.20
- Return from $14.35
- -1.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $6.56 — -54.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| -2.0% | -16.6% | -13.5% | -10.8% | -8.4% | -6.2% |
| 3.0% | -12.3% | -9.1% | -6.2% | -3.7% | -1.4% |
| 8.0% | -8.1% | -4.6% | -1.7% | 1.0% | 3.4% |
| 13.0% | -3.8% | -0.2% | 2.9% | 5.7% | 8.2% |
| 18.0% | 0.5% | 4.2% | 7.4% | 10.4% | 13.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
157+213.33%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·12d ago·Neutral
InfuSystem: Strong Franchise, Weak Entry Point InfuSystem Holdings, Inc. earns a Hold rating due to mixed cash flow trends and valuation near historical averages. INFU restructuring an unprofitable GE HealthCare contract improved its margins despite a $7.1M revenue reduction, with cost savings outpacing lost sales. Wound Care and Patient Services segments show strong growth, but ERP rollout and billing issues have delayed cash collections and pressured free cash flow.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
InfuSystem Holdings, Inc. (INFU) Q3 2026 Earnings Call Transcript InfuSystem Holdings, Inc. ( INFU ) Q3 2026 Earnings Call November 10, 2026 9:00 AM EST Company Participants Carrie Lachance - President, CEO & Director Barry Steele - Executive VP & CFO Conference Call Participants Stefan Eftychiou - Bristol Capital Ltd. Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division James Sidoti - Sidoti & Company, LLC Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Prese…
View source ↗ - Newsbusinesswire.com·26d ago·Neutral
InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026 ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026.
View source ↗ - Newsseekingalpha.com·59d ago·Positive
InfuSystem Holdings, Inc. (INFU) Discusses Business Overview and Growth Strategy with Focus on Patient-First Approach Transcript InfuSystem Holdings, Inc. (INFU) Discusses Business Overview and Growth Strategy with Focus on Patient-First Approach Transcript
View source ↗ - Newsbusinesswire.com·66d ago·Neutral
InfuSystem to Host Investor Webcast on September 24, 2026 ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Host Investor Webcast on September 24, 2026.
View source ↗
Earnings
Wed, Mar 17(in 4 months)
Consensus estimate $0.14 per share
Typical surprise +42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.15 vs $0.13beat
- Tue, Aug 4$0.15 vs $0.10beat
- Thu, May 7$0.05 vs $0.04beat
- Tue, Feb 24$0.10 vs $0.07beat
- Tue, Nov 4$0.11 vs $0.08beat
- Tue, Aug 5$0.12 vs $0.03beat
Estimates and results for INFU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INFU officers and directors.
- Bought
- $227k
- Sold
- $56k
10 trades
1 trade
- Lachance Carriebought
- Gendron Paul Andrewbought
- Lachance Carriebought
- Steele Barry Gbought
- Steele Barry Gbought
- Shuda Scottsold
- Eichenbaum Kenneth D.bought
- Hundzinski Ronald Tbought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INFU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
